Cochlear: Rethinking the market-share debate through R&D progress, rating kept Neutral

Overview

This report focuses on the market-share debate surrounding Cochlear Ltd. in the cochlear implant market. Goldman Sachs notes that after COH's downgrade in the April 22 trading update, valuation multiples in FY26 were significantly compressed, and investors are concerned whether its roughly 60% global market share remains defensible, especially as competitors like Envoy and MED-EL push fully implantable cochlear implants while Nexa's early commercial traction is below expectations. The report concludes with a Neutral rating, but argues that TICI, drug-eluting electrodes, Nexa feature upgrades, and service business could serve as medium- to long-term catalysts.

Core views

The core views are: first, COH has indeed acknowledged market-share pressure in FY25 and 1H26, but cochlear implant share has a product-cycle dynamic, and future clinical data and new product features are key to share movement. Second, TICI is one of COH's most important medium- to long-term upside catalysts, and if regulatory approval is obtained around FY29, sensitivity analysis suggests COH cochlear implant unit forecasts could be about 16.2% above base by FY30. Third, Nexa is constrained in the short term by pricing, reimbursement, and clinical proof requirements, but new features, improved U.S. reimbursement, and German study results may support stronger longer-term adoption. Fourth, DEE may lower impedance, but it has not yet been fully proven to improve auditory outcomes, making subsequent clinical data very important.

Analysis framework

The report analyzes COH market share through three primary lines: first, estimating historical share changes using COH, Advanced Bionics, and MED-EL revenue data; second, comparing clinical trials and R&D pipelines among COH, MED-EL, Envoy, and Advanced Bionics; and third, conducting share-sensitivity analysis to quantify the impact on COH cochlear implant shipments under different competitive and new-product launch scenarios.

Methodology notes

• Market share analysisRevenue and shipment-share comparison

  Determine COH share trends through revenue, competitor accounts, and unit forecasts

  Goldman Sachs compares COH revenue with Advanced Bionics public accounts from Sonova and MED-EL private accounts to estimate cochlear implant market share and total market growth.

• Scenario analysisMarket share sensitivity analysis

  COH cochlear implant unit forecasts under base, downside, and upside scenarios

  The report sets scenarios with share down about 100 bps, down about 500 bps, and up about 1000 bps from TICI and other new products to measure FY26-FY30 shipment differences.

• R&D pipeline reviewClinical trial and product differentiation comparison

  Compare R&D programs including TICI, Nexa, DEE, electrode stimulation, and processors

  The report focuses on differences between COH, MED-EL, Envoy, and Advanced Bionics in efficacy, safety, MRI compatibility, processor choice, and regulatory timelines.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Cochlear Ltd. (COH.AX)

  Research subject

  Strengths

  Global cochlear implant leader with roughly 60% share, a TICI design that enables switching between external and internal processors with potential MRI compatibility differentiation, and R&D catalysts from Nexa and DEE.

  Weaknesses

  Short-term share pressure, Nexa underwhelming early rollout, DEE has not yet proven hearing outcome improvement, and early TICI safety data include device malfunction issues.

  Comparison

  Compared with Envoy, COH TICI has stronger early efficacy but weaker safety; compared with MED-EL, COH trial design has differentiation in MRI exclusion criteria and commercial scale.

  Risks

  Competitors launching first, slower-than-expected Nexa adoption, disappointing clinical data, and weakening growth in developed markets.

• Envoy Medical (NASDAQ: COCH)

  New TICI entrant

  Strengths

  Acclaim is a fully implantable design, with no serious adverse events in early 6-month data across 10 patients; approval and launch may occur by end-2027 to early-2028.

  Weaknesses

  Six-month CNC word gains are lower than COH TICI, MRI compatibility is not yet clear, and the chest battery and middle-ear sensor may introduce a physician learning curve.

  Comparison

  Safety looks better early on than COH’s feasibility study, but efficacy and flexibility are not as strong as COH's external/internal switchable approach.

  Risks

  Regulatory delay, clinical learning curve, insufficient efficacy, and slow commercial adoption.

• MED-EL

  Core competitor

  Strengths

  Advancing both TICI and drug-eluting electrode clinical work; residual hearing-preserving FDA indication may have already supported share gains.

  Weaknesses

  Some TICI trials have smaller sample sizes, and MRI-related exclusion criteria are relatively less favorable than COH.

  Comparison

  MED-EL can support external and internal hearing modes similarly to COH, but COH's scale and some design differentiation are more pronounced.

  Risks

  If clinical data are superior to COH, it could further pressure COH share.

• Advanced Bionics

  Core competitor

  Strengths

  Remote programming innovation helped lift share in 2H24-FY25; CY26 new processor is an important near-term watchpoint.

  Weaknesses

  The report notes it also faces near-term competitive pressure, which may indicate some COH share recovery.

  Comparison

  AB appears more dependent on processor innovation in the near term, while COH's longer-term upside is more tied to the TICI, Nexa, and DEE combination.

  Risks

  If the new processor performs strongly, it could again reshape near-term share.

Key data

• Estimated COH market shareabout 60%-63%Charts show COH remained the global leader in cochlear implants from 2022 to 2025, but 2025 reported share was somewhat lower on a revenue basis.
• US revenue shareabout 50%The report states the US is a key COH market; charts show Americas account for around 48%.
• US Medicare reimbursement changeabout +5.9% to +6% in 2026Higher reimbursement in the US supports Nexa rollout where clinic capacity remains constrained.
• TICI upside scenarioFY30 COH cochlear implant units about 16.2% above baseScenario 3 assumes TICI and other new products lift share by around 1000 bps versus base.
• COH TICI efficacy6-month EH +38.5%, IH +25.2%; 12-month EH +51.4%, IH +39.4%CNC words-in-quiet improved versus baseline; external hearing mode efficacy was higher than internal hearing mode.
• COH TICI safetydevice-related serious adverse events in 2 out of 10 patientsIn the early feasibility study, about 20% of patients experienced device issues and required reimplantation with a conventional device.
• Envoy Acclaim 6-month efficacyfrom 15.2% to 39.2%, 24% improvementBelow the 6-month improvements seen with COH TICI in both external and internal hearing modes.
• DEE impedance outcomeabout 54% reductionCI-DEX shows COH drug-eluting electrodes can reduce impedance, but hearing and speech outcomes were not improved in tandem.

Impact & implications

The investment implication is that COH's current valuation discount reflects market concerns about share defensibility and Nexa rollout. If developed-market growth recovers with clearer visibility, Nexa features and clinical evidence improve, DEE proves hearing benefit, and TICI advances smoothly around FY29, COH could regain valuation support. Conversely, if Envoy or MED-EL lead in TICI, residual hearing preservation, or processor innovation, COH share-down risk may persist.

Risks

• Nexa adoption speed remains below expectations, especially in reimbursement-constrained regions such as Germany.
• Envoy or MED-EL lead TICI commercialization timing and capture patient and physician mindshare.
• Subsequent COH TICI safety or efficacy data fail to meet expectations.
• DEE lowers impedance but is unable to demonstrate hearing outcome improvement.
• Cochlear implant growth in developed markets is below expectations.
• Advanced Bionics CY26 new processor creates near-term share pressure.

What to watch

• COH drug-eluting electrode clinical data updates for 2HCY26 to FY27.
• Advanced Bionics CY26 new processor launch and market feedback.
• COH TICI trials in Australia and for CE Mark, expected to complete around October 2027.
• COH US TICI trial, expected to complete in August 2028.
• German Nexa efficacy study versus prior-generation product, expected to complete in 2028.
• Cochlear implant demand and reimbursement environment in developed markets, especially changes in US Medicare payments.
• Envoy Acclaim 12-month data, 2Q27 FDA submission plan, and potential commercialization from late 2027 to early 2028.